Protein Kinase C Beta Inhibitors (KAI Pharmaceuticals)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameProtein Kinase C Beta Inhibitors (KAI Pharmaceuticals)
Drug Alias NameBeta PKC Inhibitors (KAI Pharmaceuticals)Protein Kinase C Beta 1 and Beta 2 Inhibitors (KAI Pharmaceuticals)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionProtein kinase C beta inhibitors
TargetsProtein kinase C beta
Therapy Area/IndicationsMacular DegenerationDiabetic Retinopathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesKai Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKai Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsMacular DegenerationDiabetic Retinopathy

Other Information

ATC CodeN/A
Related LinksN/A